Rezera Launches Up to $216.7 Million IPO
Boston drug developer Rezera opened its US initial public offering roadshow, pricing 16.7 million shares between $11 and $13 apiece.
Updated on Nov. 5, 2026 in Biotech
Live Poll
Would you invest in a newly listed biotech company's IPO?
Rezera, a drug developer based in Boston, Massachusetts, launched its US initial public offering roadshow on Thursday, November 5, 2026, seeking up to $216.7 million. GSK agreed to buy up to $25 million of shares from the offering, and Rezera will list on the Nasdaq under the symbol RZRA.
Why it matters
The offering arrives as biotech companies test public markets, with Aspen Neuroscience and Bambusa Therapeutics listing in New York last week and Swiss drug developer Windward Bio having filed for a New York IPO last month. Rezera's lead experimental product candidate, ruvonoflast, has completed mid-stage trials, and the IPO would provide funds for its portfolio of drugs targeting inflammatory drivers of cardiovascular and neurologic diseases.
Rezera is seeking up to $216.7 million by offering 16.7 million shares priced between $11 and $13 apiece, against $3.9 million in cash and cash equivalents as of June 30. At the top of the marketed range, the company would be valued at $270 million.
The players
GSK
GSK is a global drugmaker that agreed to buy up to $25 million of shares in Rezera's offering and has an existing agreement with the company.
Rezera
Rezera is a Boston-based drug developer focused on inflammatory drivers of cardiovascular and neurologic diseases, with ruvonoflast as its lead candidate.
The details
Jefferies, TD Cowen and Cantor are joint bookrunners, with Wedbush PacGrow serving as lead manager. Since 2016, Rezera has raised roughly $200 million in equity financing, and earlier this month it struck a right of first negotiation and a clinical advisory board agreement with GSK.
Timeline
June 30: Rezera reported $3.9 million in cash and cash equivalents.
Late October 2026: Aspen Neuroscience and Bambusa Therapeutics went public in New York.
November 2026: Rezera struck its agreement with GSK.
Thursday, November 5, 2026: Rezera launched its US IPO roadshow.
January 2027: Rezera's cash is expected to support operations into this month.
Market Landscape
Rezera's offering follows Aspen Neuroscience and Bambusa Therapeutics, which went public in New York last week, and Windward Bio's IPO filing last month. Together these moves extend a pattern of drug developers testing public markets for capital.
Retail investors considering the offering would be buying shares in a company whose cash covered only $3.9 million as of June 30, with operations projected to last into January 2027. The price range and GSK's purchase commitment are the key figures to watch when the offering prices.
The takeaway
For investors, Rezera's offering is a reminder that early-stage drug developers often depend on new equity raises to fund trials. Watching the final price relative to the $11 to $13 range will show how the market values the company's pipeline.
What happens next
Rezera's IPO is expected to price after the roadshow concludes, and its shares will begin trading on the Nasdaq under RZRA once listed.
Further reading
For broader coverage of drug developers and their funding, see Biotech.
Source note: This article includes information reported by WTAQ News Talk | 97.5 FM · 1360 AM | Green Bay, WI.
Live Poll
Would you invest in a newly listed biotech company's IPO?
